148 related articles for article (PubMed ID: 31022472)
21. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
22. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.
Ge X; Wang H; Zeng H; Jin X; Sujie A; Xu C; Liu Y; Huang J; Ji Y; Tan Y; Liu T; Hou Y; Qin J; Sun Y; Qin X
Hum Pathol; 2015 Jun; 46(6):850-7. PubMed ID: 25863425
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
25. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.
Ahn S; Hong M; Van Vrancken M; Lyou YJ; Kim ST; Park SH; Kang WK; Park YS; Jung SH; Woo M; Lee J; Kim KM
Mol Diagn Ther; 2016 Aug; 20(4):375-83. PubMed ID: 27179810
[TBL] [Abstract][Full Text] [Related]
26. HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization.
Kıvrak H; Özakıncı H; Karasoy D; Dizbay Sak S
Balkan Med J; 2022 Jan; 39(1):21-29. PubMed ID: 34928234
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.
Kuboki Y; Yamashita S; Niwa T; Ushijima T; Nagatsuma A; Kuwata T; Yoshino T; Doi T; Ochiai A; Ohtsu A
Ann Oncol; 2016 Jan; 27(1):127-33. PubMed ID: 26489445
[TBL] [Abstract][Full Text] [Related]
28. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
Saito M; Yamashita K; Arimura Y; Kaneto H; Okuda H; Nojima M; Hagiwara T; Suzuki K; Adachi T; Goto A; Nakachi K; Yawata A; Yoshimoto M; Tanuma T; Adachi Y; Yamaoka S; Mizukoshi T; Kawayama M; Hamamoto Y; Shinomura Y
Acta Oncol; 2016; 55(3):309-17. PubMed ID: 26757197
[TBL] [Abstract][Full Text] [Related]
29. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
33. Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers.
Tay TKY; Tan GS; Lee SH; Sam XX; Lim TH; Ng JWK; Tan DSW; Lim TKH
Pathology; 2024 Apr; 56(3):325-333. PubMed ID: 38195375
[TBL] [Abstract][Full Text] [Related]
34. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
35. High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors.
Hansen TV; Vikesaa J; Buhl SS; Rossing HH; Timmermans-Wielenga V; Nielsen FC
BMC Cancer; 2015 Feb; 15():35. PubMed ID: 25655188
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implication of
Jung J; Kim ST; Ko J; Hong JY; Park JO; Ha SY; Lee J
JCO Precis Oncol; 2023 Jul; 7():e2200537. PubMed ID: 37499191
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
Kondo Y; Kikuchi T; Esteban JC; Kumaki N; Ogura G; Inomoto C; Hirabayashi K; Kajiwara H; Sakai A; Sugimoto R; Otsuru M; Okami K; Tsukinoki K; Nakamura N
Pathol Int; 2014 Sep; 64(9):453-9. PubMed ID: 25209856
[TBL] [Abstract][Full Text] [Related]
38. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
39. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
40. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
